Stellate ganglion block for treating post-COVID-19 parosmia.
Bita R NaimiEmily GarveyMegha ChandnaAlexander DuffyStephanie R HunterShreya MandloiChase KahnDouglas FarquharGlen E D'SouzaMindy RabinowitzMarc RosenElina ToskalaJohannes B RoedlAdam ZogaGurston NyquistDavid RosenPublished in: International forum of allergy & rhinology (2024)
SGB may improve subjective parosmia and QOL for patients with post-COVID OD, however it may not affect odor identification. Further placebo-controlled studies are warranted.
Keyphrases
- coronavirus disease
- sars cov
- placebo controlled
- double blind
- respiratory syndrome coronavirus
- neuropathic pain
- randomized controlled trial
- study protocol
- sleep quality
- spinal cord
- spinal cord injury
- phase ii
- physical activity
- depressive symptoms
- radiation therapy
- optical coherence tomography
- bioinformatics analysis
- optic nerve